University of New Mexico researchers are joining a multi-site clinical trial of an experimental psychedelic drug intended to alleviate the mental suffering many patients experience when they receive a life-altering disease diagnosis. In this episode of It’s Probably Not Rocket Science, lead researcher Dr. Lawrence Leeman, professor in the Department of Family & Community Medicine at the UNM School of Medicine, discusses the REKINDLE trial that will test the effectiveness of RE104, a synthetic “prodrug” that is chemically similar to psilocybin, the active ingredient in so-called magic mushrooms.